Holden Comprehensive Cancer Center 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
NCT00935038: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Active, not recruiting
2
18
US, RoW
selenomethionine, placebo
Roswell Park Cancer Institute
Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
04/12
 
NCT05363631: Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Recruiting
1/2
55
US
Selenomethionine (SLM), Axitinib, Pembrolizumab
Mohammed Milhem, University of Iowa
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
12/26
12/26
OSCAR, NCT04952129: Optimal Selenium for Bowel Polyps

Active, not recruiting
1
56
RoW
Selenomethionine, L-selenomethionine, Methylselenocysteine, Se-methyl-selenocysteine
University of Auckland, New Zealand, Cancer Trials New Zealand, Counties Manukau Health, Waikato Hospital
Colorectal Adenoma
06/24
08/24
NCT02535533: SLM + Axitinib for Clear Cell RCC

Completed
1
46
US
Selenomethionine (SLM), Axitinib
Mohammed Milhem, Pfizer
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
08/23
04/25
NCT06867913: A Study of Selenomethionine and Myo-inositol(SOLOWAYS_TM) in Patients With Autoimmune Thyroiditis Carrying the DIO2 Thr92Ala Polymorphism

Completed
N/A
40
RoW
Supplement groupx
S.LAB (SOLOWAYS), Center for New Medical Technologies, Novosibirsk, Russia
Autoimmune Thyroiditis
12/24
02/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
selenomethionine (SLM) / Holden Comprehensive Cancer Center, The University of Iowa
NCT00935038: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Active, not recruiting
2
18
US, RoW
selenomethionine, placebo
Roswell Park Cancer Institute
Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
04/12
 
NCT05363631: Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Recruiting
1/2
55
US
Selenomethionine (SLM), Axitinib, Pembrolizumab
Mohammed Milhem, University of Iowa
Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic
12/26
12/26
OSCAR, NCT04952129: Optimal Selenium for Bowel Polyps

Active, not recruiting
1
56
RoW
Selenomethionine, L-selenomethionine, Methylselenocysteine, Se-methyl-selenocysteine
University of Auckland, New Zealand, Cancer Trials New Zealand, Counties Manukau Health, Waikato Hospital
Colorectal Adenoma
06/24
08/24
NCT02535533: SLM + Axitinib for Clear Cell RCC

Completed
1
46
US
Selenomethionine (SLM), Axitinib
Mohammed Milhem, Pfizer
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
08/23
04/25
NCT06867913: A Study of Selenomethionine and Myo-inositol(SOLOWAYS_TM) in Patients With Autoimmune Thyroiditis Carrying the DIO2 Thr92Ala Polymorphism

Completed
N/A
40
RoW
Supplement groupx
S.LAB (SOLOWAYS), Center for New Medical Technologies, Novosibirsk, Russia
Autoimmune Thyroiditis
12/24
02/25

Download Options